Meribank Biotech Co., Ltd (TPEX:4724)

Meribank Biotech Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	69.22	97.44	165.09	399.46	85.16	192.15
Short-Term Investments	122.1	131.9	-	-	122.7	94.1
Cash & Short-Term Investments	191.32	229.34	165.09	399.46	207.86	286.25
Cash Growth	40.47%	38.92%	-58.67%	92.18%	-27.39%	194.21%
Accounts Receivable	190.82	187.12	158.22	128.63	146.97	147.53
Other Receivables	-	6.08	8.82	6.5	5.47	1.63
Receivables	190.82	193.21	167.04	135.13	152.44	149.17
Inventory	5.64	6.42	11.24	6.91	8.45	3.6
Prepaid Expenses	37.8	40.27	49.6	28.61	24.13	19.87
Other Current Assets	0.52	1.39	0.34	0.09	0.02	0.11
Total Current Assets	426.1	470.63	393.31	570.19	392.9	458.99
Property, Plant & Equipment	453.77	473.71	479.46	162.06	178.19	190.76
Long-Term Investments	46.74	39.13	59.57	59.56	25.22	44.45
Goodwill	-	280.08	282.18	2.87	-	-
Other Intangible Assets	809.3	548.24	584.09	31.69	10.22	1.09
Long-Term Deferred Tax Assets	4.51	4.26	3.8	2.48	-	-
Other Long-Term Assets	1,015	1,060	879.54	233.17	239.8	252.03
Total Assets	2,755	2,876	2,682	1,062	846.33	947.32

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	7.63	6.92	13.08	12.32	7.6	4.75
Accrued Expenses	-	60.17	63.31	50.63	45.84	44.57
Current Portion of Long-Term Debt	-	7.46	7.32	-	-	-
Current Portion of Leases	137.81	126.83	70.85	19.23	21.58	18.25
Current Unearned Revenue	21.65	22.47	27.33	17.56	14.76	12.97
Other Current Liabilities	82.89	23.71	50.35	27.17	19.28	15.34
Total Current Liabilities	249.97	247.55	232.23	126.91	109.07	95.87
Long-Term Debt	151.63	155.41	162.88	-	-	-
Long-Term Leases	788.14	837.96	701.79	14.81	24.25	34.73
Long-Term Unearned Revenue	267.21	272.52	258.41	245.7	236.52	228.14
Long-Term Deferred Tax Liabilities	90.35	93.51	99.83	1.38	0.65	-
Other Long-Term Liabilities	19.8	9.35	9.42	2.02	2.05	2.53
Total Liabilities	1,567	1,616	1,465	390.81	372.53	361.27

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	959.76	959.76	879.76	709.76	627.76	627.76
Additional Paid-In Capital	306.03	748.27	708.27	233.2	203.24	203.74
Retained Earnings	-72.67	-454.7	-373.23	-272.2	-350.09	-247.58
Comprehensive Income & Other	-15.31	-4.19	-9.07	-9.04	-9.71	2.12
Total Common Equity	1,178	1,249	1,206	661.73	471.2	586.05
Minority Interest	10.48	10.96	11.65	9.46	2.59	-
Shareholders' Equity	1,188	1,260	1,217	671.2	473.79	586.05
Total Liabilities & Equity	2,755	2,876	2,682	1,062	846.33	947.32

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	1,078	1,128	942.84	34.04	45.83	52.97
Net Cash (Debt)	-886.26	-898.33	-777.75	365.42	162.03	233.28
Net Cash Growth	-	-	-	125.53%	-30.54%	752.06%
Net Cash Per Share	-9.25	-9.84	-9.78	5.81	2.58	3.87
Filing Date Shares Outstanding	95.62	95.98	87.98	70.98	62.78	62.78
Total Common Shares Outstanding	95.62	95.98	87.98	70.98	62.78	62.78
Working Capital	176.13	223.08	161.08	443.27	283.83	363.12
Book Value Per Share	12.32	13.02	13.71	9.32	7.51	9.34
Tangible Book Value	368.52	420.83	339.46	627.17	460.98	584.96
Tangible Book Value Per Share	3.85	4.38	3.86	8.84	7.34	9.32
Land	-	214.7	214.7	41.08	41.08	41.08
Buildings	-	107.62	107.62	53.84	53.23	52.95
Machinery	-	103.23	96.57	76.56	61.45	62.83

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 25, 2026

Data Sources Report a data error